Global Buccal Drug Delivery Systems

Buccal Drug Delivery Systems Comprehensive Study by Active Ingredients (Insulin, Nicotin, Nifedipine, Flubiprofen, Others), Formulation (Sublingual Films, Tablets, Sprays), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2030

Buccal Drug Delivery Systems Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Buccal Drug Delivery Systems
The global Buccal Drug Delivery Systems market is expected to witness high demand due to the increasing healthcare expenditure of the developing countries. The buccal drug delivery system is a therapeutic option that delivers drugs through buccal mucosal lines. Through the buccal drug delivery system, the desired therapeutic dose of the drug gets immediately absorbed into plasma and the consistency of the concentration can be maintained throughout the duration of the treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)


Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on increasing their client base to strengthen market position and to enhance product & service offerings. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Buccal Drug Delivery Systems market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ethypharm (France), Cynapsus (Canada), Ardea Biosciences (United States), Applied Pharma Research (United States), BioDelivery Sciences (United States), Actavis (United States), Endo Pharmaceutical (Ireland), GlaxoSmithKline plc. (United Kingdom), Indivior Pharmaceuticals (United Kingdom) and Generex Biotechnology (Canada) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bayer (Germany), Dr.Reddy's (India), Novartis (Switzerland) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Buccal Drug Delivery Systems market by and Region.



On the basis of geography, the market of Buccal Drug Delivery Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by Active Ingredients, the sub-segment i.e. Insulin will boost the Buccal Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Formulation, the sub-segment i.e. Sublingual Films will boost the Buccal Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Buccal Drug Delivery Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Rapid Absorption of Drugs into Plasma and Rise in Preference to Macromolecules including Peptides, Absorption Enhancers, etc.,

Market Growth Drivers:
The Growing use of Smaller Molecules and High Adoption due to Availability of Non-Ionized Drugs

Challenges:
Law Pertaining to Intellectual Property Rights in the Near Future.

Restraints:
The Concern Stringent Regulatory Conditions

Opportunities:
High Adoption due to Technological Advancement and The Rise in Mergers and Acquisitions

Market Leaders and their expansionary development strategies
In April 2023, Difgen Pharmaceuticals LLC announced that it has acquired Aveva Drug Delivery service, a fully integrated developer and manufacturer of TDS and ODF.
In June 2022, Gufic Biosciences has launched indigenous New Drug Delivery System (NDDS) named Dual Chamber Bags (DCB) at an affordable price in India.


Key Target Audience
Buccal Drug Delivery Systems Providers, Buccal Drug Delivery Systems Distributors, Buccal Drug Delivery Systems Suppliers, Government Regulatory Bodies, Private Research Organizations, Government Research Organization and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Active Ingredients
  • Insulin
  • Nicotin
  • Nifedipine
  • Flubiprofen
  • Others

By Formulation
  • Sublingual Films
  • Tablets
  • Sprays

By End User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Growing use of Smaller Molecules
      • 3.2.2. High Adoption due to Availability of Non-Ionized Drugs
    • 3.3. Market Challenges
      • 3.3.1. Law Pertaining to Intellectual Property Rights in the Near Future.
    • 3.4. Market Trends
      • 3.4.1. The Rapid Absorption of Drugs into Plasma
      • 3.4.2. Rise in Preference to Macromolecules including Peptides, Absorption Enhancers, etc.,
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Buccal Drug Delivery Systems, by Active Ingredients, Formulation, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Buccal Drug Delivery Systems (Value)
      • 5.2.1. Global Buccal Drug Delivery Systems by: Active Ingredients (Value)
        • 5.2.1.1. Insulin
        • 5.2.1.2. Nicotin
        • 5.2.1.3. Nifedipine
        • 5.2.1.4. Flubiprofen
        • 5.2.1.5. Others
      • 5.2.2. Global Buccal Drug Delivery Systems by: Formulation (Value)
        • 5.2.2.1. Sublingual Films
        • 5.2.2.2. Tablets
        • 5.2.2.3. Sprays
      • 5.2.3. Global Buccal Drug Delivery Systems by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Buccal Drug Delivery Systems Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Buccal Drug Delivery Systems (Price)
  • 6. Buccal Drug Delivery Systems: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ethypharm (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cynapsus (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ardea Biosciences (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Applied Pharma Research (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioDelivery Sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Actavis (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Endo Pharmaceutical (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Indivior Pharmaceuticals (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Generex Biotechnology (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Buccal Drug Delivery Systems Sale, by Active Ingredients, Formulation, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Buccal Drug Delivery Systems (Value)
      • 7.2.1. Global Buccal Drug Delivery Systems by: Active Ingredients (Value)
        • 7.2.1.1. Insulin
        • 7.2.1.2. Nicotin
        • 7.2.1.3. Nifedipine
        • 7.2.1.4. Flubiprofen
        • 7.2.1.5. Others
      • 7.2.2. Global Buccal Drug Delivery Systems by: Formulation (Value)
        • 7.2.2.1. Sublingual Films
        • 7.2.2.2. Tablets
        • 7.2.2.3. Sprays
      • 7.2.3. Global Buccal Drug Delivery Systems by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Buccal Drug Delivery Systems Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Buccal Drug Delivery Systems (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Buccal Drug Delivery Systems: by Active Ingredients(USD Million)
  • Table 2. Buccal Drug Delivery Systems Insulin , by Region USD Million (2018-2023)
  • Table 3. Buccal Drug Delivery Systems Nicotin , by Region USD Million (2018-2023)
  • Table 4. Buccal Drug Delivery Systems Nifedipine , by Region USD Million (2018-2023)
  • Table 5. Buccal Drug Delivery Systems Flubiprofen , by Region USD Million (2018-2023)
  • Table 6. Buccal Drug Delivery Systems Others , by Region USD Million (2018-2023)
  • Table 7. Buccal Drug Delivery Systems: by Formulation(USD Million)
  • Table 8. Buccal Drug Delivery Systems Sublingual Films , by Region USD Million (2018-2023)
  • Table 9. Buccal Drug Delivery Systems Tablets , by Region USD Million (2018-2023)
  • Table 10. Buccal Drug Delivery Systems Sprays , by Region USD Million (2018-2023)
  • Table 11. Buccal Drug Delivery Systems: by End User(USD Million)
  • Table 12. Buccal Drug Delivery Systems Hospitals , by Region USD Million (2018-2023)
  • Table 13. Buccal Drug Delivery Systems Clinics , by Region USD Million (2018-2023)
  • Table 14. Buccal Drug Delivery Systems Others , by Region USD Million (2018-2023)
  • Table 15. South America Buccal Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 16. South America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 17. South America Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 18. South America Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 19. Brazil Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 20. Brazil Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 21. Brazil Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 22. Argentina Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 23. Argentina Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 24. Argentina Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 25. Rest of South America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 26. Rest of South America Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 27. Rest of South America Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 28. Asia Pacific Buccal Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 29. Asia Pacific Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 30. Asia Pacific Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 31. Asia Pacific Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 32. China Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 33. China Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 34. China Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 35. Japan Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 36. Japan Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 37. Japan Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 38. India Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 39. India Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 40. India Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 41. South Korea Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 42. South Korea Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 43. South Korea Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 44. Taiwan Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 45. Taiwan Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 46. Taiwan Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 47. Australia Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 48. Australia Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 49. Australia Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 53. Europe Buccal Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 54. Europe Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 55. Europe Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 56. Europe Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 57. Germany Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 58. Germany Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 59. Germany Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 60. France Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 61. France Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 62. France Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 63. Italy Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 64. Italy Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 65. Italy Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 66. United Kingdom Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 67. United Kingdom Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 68. United Kingdom Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 69. Netherlands Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 70. Netherlands Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 71. Netherlands Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 72. Rest of Europe Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 73. Rest of Europe Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 74. Rest of Europe Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 75. MEA Buccal Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 76. MEA Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 77. MEA Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 78. MEA Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 79. Middle East Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 80. Middle East Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 81. Middle East Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 82. Africa Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 83. Africa Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 84. Africa Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 85. North America Buccal Drug Delivery Systems, by Country USD Million (2018-2023)
  • Table 86. North America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 87. North America Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 88. North America Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 89. United States Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 90. United States Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 91. United States Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 92. Canada Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 93. Canada Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 94. Canada Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 95. Mexico Buccal Drug Delivery Systems, by Active Ingredients USD Million (2018-2023)
  • Table 96. Mexico Buccal Drug Delivery Systems, by Formulation USD Million (2018-2023)
  • Table 97. Mexico Buccal Drug Delivery Systems, by End User USD Million (2018-2023)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Buccal Drug Delivery Systems: by Active Ingredients(USD Million)
  • Table 109. Buccal Drug Delivery Systems Insulin , by Region USD Million (2025-2030)
  • Table 110. Buccal Drug Delivery Systems Nicotin , by Region USD Million (2025-2030)
  • Table 111. Buccal Drug Delivery Systems Nifedipine , by Region USD Million (2025-2030)
  • Table 112. Buccal Drug Delivery Systems Flubiprofen , by Region USD Million (2025-2030)
  • Table 113. Buccal Drug Delivery Systems Others , by Region USD Million (2025-2030)
  • Table 114. Buccal Drug Delivery Systems: by Formulation(USD Million)
  • Table 115. Buccal Drug Delivery Systems Sublingual Films , by Region USD Million (2025-2030)
  • Table 116. Buccal Drug Delivery Systems Tablets , by Region USD Million (2025-2030)
  • Table 117. Buccal Drug Delivery Systems Sprays , by Region USD Million (2025-2030)
  • Table 118. Buccal Drug Delivery Systems: by End User(USD Million)
  • Table 119. Buccal Drug Delivery Systems Hospitals , by Region USD Million (2025-2030)
  • Table 120. Buccal Drug Delivery Systems Clinics , by Region USD Million (2025-2030)
  • Table 121. Buccal Drug Delivery Systems Others , by Region USD Million (2025-2030)
  • Table 122. South America Buccal Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 123. South America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 124. South America Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 125. South America Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 126. Brazil Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 127. Brazil Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 128. Brazil Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 129. Argentina Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 130. Argentina Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 131. Argentina Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 132. Rest of South America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 133. Rest of South America Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 134. Rest of South America Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 135. Asia Pacific Buccal Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 136. Asia Pacific Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 137. Asia Pacific Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 138. Asia Pacific Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 139. China Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 140. China Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 141. China Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 142. Japan Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 143. Japan Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 144. Japan Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 145. India Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 146. India Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 147. India Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 148. South Korea Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 149. South Korea Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 150. South Korea Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 151. Taiwan Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 152. Taiwan Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 153. Taiwan Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 154. Australia Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 155. Australia Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 156. Australia Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 160. Europe Buccal Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 161. Europe Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 162. Europe Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 163. Europe Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 164. Germany Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 165. Germany Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 166. Germany Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 167. France Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 168. France Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 169. France Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 170. Italy Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 171. Italy Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 172. Italy Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 173. United Kingdom Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 174. United Kingdom Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 175. United Kingdom Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 176. Netherlands Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 177. Netherlands Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 178. Netherlands Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 179. Rest of Europe Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 180. Rest of Europe Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 181. Rest of Europe Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 182. MEA Buccal Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 183. MEA Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 184. MEA Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 185. MEA Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 186. Middle East Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 187. Middle East Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 188. Middle East Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 189. Africa Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 190. Africa Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 191. Africa Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 192. North America Buccal Drug Delivery Systems, by Country USD Million (2025-2030)
  • Table 193. North America Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 194. North America Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 195. North America Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 196. United States Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 197. United States Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 198. United States Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 199. Canada Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 200. Canada Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 201. Canada Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 202. Mexico Buccal Drug Delivery Systems, by Active Ingredients USD Million (2025-2030)
  • Table 203. Mexico Buccal Drug Delivery Systems, by Formulation USD Million (2025-2030)
  • Table 204. Mexico Buccal Drug Delivery Systems, by End User USD Million (2025-2030)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Buccal Drug Delivery Systems: by Active Ingredients USD Million (2018-2023)
  • Figure 5. Global Buccal Drug Delivery Systems: by Formulation USD Million (2018-2023)
  • Figure 6. Global Buccal Drug Delivery Systems: by End User USD Million (2018-2023)
  • Figure 7. South America Buccal Drug Delivery Systems Share (%), by Country
  • Figure 8. Asia Pacific Buccal Drug Delivery Systems Share (%), by Country
  • Figure 9. Europe Buccal Drug Delivery Systems Share (%), by Country
  • Figure 10. MEA Buccal Drug Delivery Systems Share (%), by Country
  • Figure 11. North America Buccal Drug Delivery Systems Share (%), by Country
  • Figure 12. Global Buccal Drug Delivery Systems share by Players 2023 (%)
  • Figure 13. Global Buccal Drug Delivery Systems share by Players (Top 3) 2023(%)
  • Figure 14. Global Buccal Drug Delivery Systems share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ethypharm (France) Revenue, Net Income and Gross profit
  • Figure 17. Ethypharm (France) Revenue: by Geography 2023
  • Figure 18. Cynapsus (Canada) Revenue, Net Income and Gross profit
  • Figure 19. Cynapsus (Canada) Revenue: by Geography 2023
  • Figure 20. Ardea Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 21. Ardea Biosciences (United States) Revenue: by Geography 2023
  • Figure 22. Applied Pharma Research (United States) Revenue, Net Income and Gross profit
  • Figure 23. Applied Pharma Research (United States) Revenue: by Geography 2023
  • Figure 24. BioDelivery Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 25. BioDelivery Sciences (United States) Revenue: by Geography 2023
  • Figure 26. Actavis (United States) Revenue, Net Income and Gross profit
  • Figure 27. Actavis (United States) Revenue: by Geography 2023
  • Figure 28. Endo Pharmaceutical (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Endo Pharmaceutical (Ireland) Revenue: by Geography 2023
  • Figure 30. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Indivior Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Indivior Pharmaceuticals (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Generex Biotechnology (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Generex Biotechnology (Canada) Revenue: by Geography 2023
  • Figure 36. Global Buccal Drug Delivery Systems: by Active Ingredients USD Million (2025-2030)
  • Figure 37. Global Buccal Drug Delivery Systems: by Formulation USD Million (2025-2030)
  • Figure 38. Global Buccal Drug Delivery Systems: by End User USD Million (2025-2030)
  • Figure 39. South America Buccal Drug Delivery Systems Share (%), by Country
  • Figure 40. Asia Pacific Buccal Drug Delivery Systems Share (%), by Country
  • Figure 41. Europe Buccal Drug Delivery Systems Share (%), by Country
  • Figure 42. MEA Buccal Drug Delivery Systems Share (%), by Country
  • Figure 43. North America Buccal Drug Delivery Systems Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ethypharm (France)
  • Cynapsus (Canada)
  • Ardea Biosciences (United States)
  • Applied Pharma Research (United States)
  • BioDelivery Sciences (United States)
  • Actavis (United States)
  • Endo Pharmaceutical (Ireland)
  • GlaxoSmithKline plc. (United Kingdom)
  • Indivior Pharmaceuticals (United Kingdom)
  • Generex Biotechnology (Canada)
Additional players considered in the study are as follows:
Bayer (Germany) , Dr.Reddy's (India) , Novartis (Switzerland) , Others
Select User Access Type

Key Highlights of Report


Mar 2024 239 Pages 72 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Buccal Drug Delivery Systems Quantitative research analysis
Global Buccal Drug Delivery Systems Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ethypharm (France), Cynapsus (Canada), Ardea Biosciences (United States), Applied Pharma Research (United States), BioDelivery Sciences (United States), Actavis (United States), Endo Pharmaceutical (Ireland), GlaxoSmithKline plc. (United Kingdom), Indivior Pharmaceuticals (United Kingdom) and Generex Biotechnology (Canada) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Rapid Absorption of Drugs into Plasma " is seen as one of major influencing trends for Buccal Drug Delivery Systems Market during projected period 2023-2030.
The Buccal Drug Delivery Systems market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Buccal Drug Delivery Systems Report?

Have a Query? Click Here

Other Related Reports

Physiotherapy Equipment Comprehensive Study by Type (Hydrotherapy Equipment, Electrotherapy Equipment, Cryotherapy Equipment, Multi-Exercise Therapy Unit Equipment, Heat Therapy Equipment, Ultrasound...
$ 3750
Hemodynamic Monitoring Systems Comprehensive Study by Type (Invasive, Minimally Invasive, Noninvasive), Application (Hospitals, Cath Labs, Home and Ambulatory Care), Devices (Pulse Contour, Oesophage...
$ 3450
Cryocooler Comprehensive Study by Type (Gifford-McMahon (GM), Pulse-Tube (PT), Stirling, Joule Thomsoz (JT), Brayton), Application (Military, Healthcare, Commercial, Environmental, Energy & Power, Tr...
$ 3750
Next Generation Sequencing Comprehensive Study by Type (Targeted Sequencing & Resequencing, Whole Genome Sequencing, Whole Exome Sequencing), Application (Whole-genome Sequencing, Exome Sequencing, T...
$ 4000
Ventilators Comprehensive Study by Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), Application (Hospitals and Clinics, Home Care, Ambulatory Care Centers, Emergency Medical Services ...
$ 3750
Forehead Thermometer Comprehensive Study by Type (Non-contact Type, Contact Type), Application (Hospital, Home Use, Others), Distribution Channel (Pharmaceuticals, Online Channel, Random Shops) Playe...
$ 3500